Skip to content
Disclosery

Propel Bio Management, LLC

Follow

13F filer, CIK 1969764, Los Angeles, CA

Propel Bio Management, LLC reported $117,123,993 across 20 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-11. Its ten largest share positions make up 83.88% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000898432-26-000087

Period
2025-12-31
Reported value
$117M
Holdings
20
Top 10 weight
83.88%
New
8
Sold out
4

Largest buys vs the previous quarter

SecurityShares changeApprox. value
KYTXnew+666,666$6.27M
VRDNadded+192,531$5.99M
IVAnew+1,000,000$4.65M
OCSnew+172,839$3.45M
PHATadded+187,991$3.12M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
AKROexited-228,884-$10.9M
Applied Therapeutics Incexited-11,285,420-$6.83M
TCRXexited-1,932,304-$3.52M
JSPRexited-1,028,806-$2.45M
MISTreduced-1,006,569-$2.03M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0000898432-26-000087, largest first. % of portfolio is the value over $117,123,993, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
PAGPPLAINS GP HLDGS L PQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 1,272,360 shares; 2024Q4: 1,272,360 shares; 2025Q1: 1,272,360 shares; 2025Q2: 1,272,360 shares; 2025Q3: 1,272,360 shares; 2025Q4: 1,272,360 shares 1,272,360$24.4M20.79%0Timeline
ACHVACHIEVE LIFE SCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 2,453,092 shares; 2024Q4: 2,453,092 shares; 2025Q1: 2,453,092 shares; 2025Q2: 6,153,091 shares; 2025Q3: 3,786,425 shares; 2025Q4: 3,786,425 shares 3,786,425$18.8M16.07%0Timeline
PHATPHATHOM PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 869,927 shares; 2024Q4: 989,927 shares; 2025Q1: 1,134,927 shares; 2025Q2: 922,927 shares; 2025Q3: 552,927 shares; 2025Q4: 740,918 shares 740,918$12.3M10.49%+187,991Timeline
VRDNVIRIDIAN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 90,000 shares; 2025Q4: 282,531 shares 282,531$8.79M7.51%+192,531Timeline
MISTMILESTONE PHARMACEUTICALS INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 1,451,557 shares; 2025Q2: 1,791,557 shares; 2025Q3: 5,124,890 shares; 2025Q4: 4,118,321 shares 4,118,321$8.32M7.1%-1,006,569Timeline
KYTXKYVERNA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 666,666 shares 666,666$6.27M5.35%newTimeline
CMPSCOMPASS PATHWAYS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 80,000 shares; 2024Q4: 25,209 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 510,000 shares; 2025Q4: 861,778 shares 861,778$5.95M5.08%+351,778Timeline
IVAINVENTIVA SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,000,000 shares 1,000,000$4.65M3.97%newTimeline
DCTHDELCATH SYS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 17,000 shares; 2025Q1: 177,600 shares; 2025Q2: 226,052 shares; 2025Q3: 438,509 shares; 2025Q4: 438,509 shares 438,509$4.43M3.78%0Timeline
ABEOABEONA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 624,022 shares; 2024Q4: 624,022 shares; 2025Q1: 624,022 shares; 2025Q2: 974,022 shares; 2025Q3: 974,022 shares; 2025Q4: 830,780 shares 830,780$4.38M3.74%-143,242Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 155,000 shares; 2025Q4: 154,300 shares 154,300$4.19M3.58%-700Timeline
NKTRNEKTAR THERAPEUTICSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 49,000 shares; 2025Q4: 82,822 shares 82,822$3.5M2.99%+33,822Timeline
OCSOCULIS HOLDING AGQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 172,839 shares 172,839$3.45M2.95%newTimeline
SABSSAB BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 652,881 shares 652,881$2.44M2.08%newTimeline
RGNXREGENXBIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 116,896 shares 116,896$1.68M1.44%newTimeline
LONALEONABIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 149,279 shares; 2025Q4: 149,279 shares 149,279$1.13M0.96%0Timeline
LENZLENZ THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 59,085 shares 59,085$945K0.81%newTimeline
AARDAARDVARK THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 46,408 shares 46,408$609K0.52%newTimeline
ZVRAZEVRA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 179,874 shares; 2024Q4: 179,874 shares; 2025Q1: 179,874 shares; 2025Q2: 231,874 shares; 2025Q3: 231,874 shares; 2025Q4: 63,683 shares 63,683$571K0.49%-168,191Timeline
KLRSKALARIS THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 42,053 shares 42,053$355K0.3%newTimeline

Sold out in Q4 2025

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
AKROAKERO THERAPEUTICS INC228,884$10.9Mshares
Applied Therapeutics IncApplied Therapeutics Inc11,285,420$6.83Mshares
TCRXTSCAN THERAPEUTICS INC1,932,304$3.52Mshares
JSPRJASPER THERAPEUTICS INC1,028,806$2.45Mshares

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000898432-26-000087 base2026-02-11acceptance time not in the bulk data set